A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
Clinical trial NCT03033511 · TERMINATED
Trial details
- NCT number
- NCT03033511
- Sponsor
- AbbVie
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-07
- Primary completion
- 2019-11-20
- Enrollment
- 748
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.